ATE466943T1 - Dns-sequenzen mit anti-repressor aktivität - Google Patents

Dns-sequenzen mit anti-repressor aktivität

Info

Publication number
ATE466943T1
ATE466943T1 AT06124491T AT06124491T ATE466943T1 AT E466943 T1 ATE466943 T1 AT E466943T1 AT 06124491 T AT06124491 T AT 06124491T AT 06124491 T AT06124491 T AT 06124491T AT E466943 T1 ATE466943 T1 AT E466943T1
Authority
AT
Austria
Prior art keywords
regulatory sequences
repressor activity
sequences
dns
dns sequences
Prior art date
Application number
AT06124491T
Other languages
English (en)
Inventor
Arie Otte
Arthur Leo Kruckeberg
Original Assignee
Chromagenics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202581A external-priority patent/EP1273666A1/de
Application filed by Chromagenics Bv filed Critical Chromagenics Bv
Application granted granted Critical
Publication of ATE466943T1 publication Critical patent/ATE466943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06124491T 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität ATE466943T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202581A EP1273666A1 (de) 2001-07-04 2001-07-04 Verfahren zur Selektion einer transkription-modulatierenden DNA-Sequenz unter Verwendung einem Vektor mit einem transkriptions-repressions-aktivem Element
US30319901P 2001-07-05 2001-07-05
US10/190,312 US7192741B2 (en) 2001-07-04 2002-07-05 DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences

Publications (1)

Publication Number Publication Date
ATE466943T1 true ATE466943T1 (de) 2010-05-15

Family

ID=47915807

Family Applications (8)

Application Number Title Priority Date Filing Date
AT05076209T ATE358183T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124475T ATE466942T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124470T ATE466941T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124481T ATE466944T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT02741531T ATE343004T1 (de) 2001-07-04 2002-06-14 Verfahren zur selektion einer transkription- modulatierenden dna-sequenz unter verwendung einem vektor mit einem transkriptions-repressions-aktivem element
AT06124491T ATE466943T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124465T ATE474053T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124482T ATE467682T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität

Family Applications Before (5)

Application Number Title Priority Date Filing Date
AT05076209T ATE358183T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124475T ATE466942T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124470T ATE466941T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124481T ATE466944T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT02741531T ATE343004T1 (de) 2001-07-04 2002-06-14 Verfahren zur selektion einer transkription- modulatierenden dna-sequenz unter verwendung einem vektor mit einem transkriptions-repressions-aktivem element

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06124465T ATE474053T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124482T ATE467682T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität

Country Status (21)

Country Link
US (9) US7192741B2 (de)
EP (8) EP1806407B1 (de)
JP (3) JP4500044B2 (de)
KR (2) KR100942116B1 (de)
CN (1) CN1266282C (de)
AT (8) ATE358183T1 (de)
AU (3) AU2002314629B2 (de)
BR (1) BRPI0210771B8 (de)
CA (2) CA2450020C (de)
CY (1) CY1107678T1 (de)
DE (8) DE60237048D1 (de)
DK (8) DK1829972T3 (de)
ES (8) ES2344072T3 (de)
IL (4) IL159674A0 (de)
MX (1) MXPA03011801A (de)
NO (1) NO338477B1 (de)
NZ (1) NZ530218A (de)
PT (1) PT1600510E (de)
SG (1) SG143066A1 (de)
WO (1) WO2003004704A2 (de)
ZA (1) ZA200309599B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806407B1 (de) 2001-07-04 2010-05-05 Chromagenics B.V. DNS-Sequenzen mit Anti-Repressor-Aktivität
EP1513936A2 (de) 2002-06-14 2005-03-16 Chromagenics B.V. Verwendung von repression hemmende sequenzen in verfahren zur genexpression verbesserung
DK1513937T3 (da) 2002-06-14 2011-05-16 Chromagenics Bv Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
EP2314629B2 (de) 2002-07-18 2022-11-16 Merus N.V. Rekombinante Herstellung von Mischungen aus Aantikörpern
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2510179C (en) 2002-12-18 2013-04-23 Chromagenics B.V. A method for improving protein production
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
KR101203817B1 (ko) 2003-10-02 2012-11-23 크루셀 홀란드 비.브이. 재조합 아데노바이러스를 위한 포장 세포
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
WO2006005718A2 (en) * 2004-07-08 2006-01-19 Chromagenics B.V. Novel sequence for improving expression of nucleic acid
PT1786908E (pt) * 2004-08-18 2010-04-29 Bayer Cropscience Ag Plantas com um aumento da actividade da enzima de fosforilação do amido r3 nos plastídeos
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
PL1809750T3 (pl) 2004-11-08 2012-08-31 Chromagenics Bv Selekcja komórki gospodarza eksprymującej białko na wysokich poziomach
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
CN101090968B (zh) 2004-11-08 2011-10-26 科罗迈吉尼科斯公司 高水平表达蛋白质的宿主细胞的选择
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7968700B2 (en) 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008085956A2 (en) * 2007-01-08 2008-07-17 Millipore Corporation High expression cell line that eliminates gene amplification
EP2443239B1 (de) 2009-06-15 2015-11-25 Cellagenics B.V. Neue stringent selektionsmarker
US8566596B2 (en) 2010-08-24 2013-10-22 Cisco Technology, Inc. Pre-association mechanism to provide detailed description of wireless services
US9650630B2 (en) 2010-09-01 2017-05-16 Cellagenics B.V. Nucleic acid fragments from a ribosomal protein promoter for enhancing gene expression
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
US10417380B1 (en) 2013-12-31 2019-09-17 Mckesson Corporation Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
US10489552B2 (en) 2014-02-14 2019-11-26 Mckesson Corporation Systems and methods for determining and communicating patient incentive information to a prescriber
EP3786186A1 (de) 2014-02-28 2021-03-03 Merus N.V. Egfr- und erbb3-bindende antikörper
SMT202500020T1 (it) 2014-02-28 2025-03-12 Merus Nv Anticorpo che lega erbb-2 ed erbb-3
US10157262B1 (en) 2015-03-10 2018-12-18 Mckesson Corporation Systems and methods for determining patient financial responsibility for multiple prescription products
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
US11514137B1 (en) 2016-03-30 2022-11-29 Mckesson Corporation Alternative therapy identification system
US10999224B1 (en) 2017-02-01 2021-05-04 Mckesson Corporation Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
US10862832B1 (en) 2018-07-24 2020-12-08 Mckesson Corporation Computing system and method for automatically reversing an action indicated by an electronic message
US11043437B2 (en) 2019-01-07 2021-06-22 Applied Materials, Inc. Transparent substrate with light blocking edge exclusion zone
US12525327B1 (en) 2019-06-26 2026-01-13 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
US11562437B1 (en) 2019-06-26 2023-01-24 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US11636548B1 (en) 2019-06-26 2023-04-25 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US12469040B1 (en) 2019-06-26 2025-11-11 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
EP3772518A1 (de) 2019-08-07 2021-02-10 Merus N.V. Modifizierte menschliche variable domänen
WO2021155369A1 (en) * 2020-01-31 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to identify genetic silencers and applications thereof
US11610240B1 (en) 2020-02-17 2023-03-21 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
US12229834B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
US12229833B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for reformatting an electronic prescription transaction
KR20230013030A (ko) 2020-05-21 2023-01-26 메뤼스 엔.페. Ig-유사 분자의 생산을 위한 방법 및 수단
US11587657B2 (en) 2020-09-04 2023-02-21 Mckesson Corporation Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message
US12367954B1 (en) 2021-01-08 2025-07-22 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
US12518304B1 (en) 2021-01-26 2026-01-06 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
CN113539357B (zh) * 2021-06-10 2024-04-30 阿里巴巴达摩院(杭州)科技有限公司 基因检测方法、模型训练方法、装置、设备及系统
US12197972B1 (en) 2022-03-28 2025-01-14 Mckesson Corporation Method, apparatus, and computer program product for generating alternative evaluation messages

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US719271A (en) * 1902-01-13 1903-01-27 Solomon P Smith Furnace.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5972605A (en) * 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
AU699275B2 (en) * 1995-03-24 1998-11-26 Shionogi & Co., Ltd. DNA molecule relating to suppression of gene expression and novel protein
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6037525A (en) * 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100365127C (zh) 1998-07-21 2008-01-30 密理博公司 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
DK1104490T3 (da) 1998-08-14 2008-01-02 Chromagenics Bv Fremgangsmåde til påvisning af en DNA-sekvens, DNA-sekvens, fremgangsmåde til fremstilling af en DNA-konstruktion samt anvendelse deraf
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU1128400A (en) 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US6413744B1 (en) * 1999-08-25 2002-07-02 Immunex Corporation Methods and host cells for improved cell culture
US20030166042A1 (en) 2000-02-11 2003-09-04 Millennium Pharmaceuticals, Inc. Novel seven-transmembrane proteins/G-protein coupled receptors
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
AU9006701A (en) 2000-09-20 2002-04-02 Cobra Therapeutics Ltd Polynucleotide
EP1273666A1 (de) 2001-07-04 2003-01-08 Chromagenics B.V. Verfahren zur Selektion einer transkription-modulatierenden DNA-Sequenz unter Verwendung einem Vektor mit einem transkriptions-repressions-aktivem Element
EP1806407B1 (de) 2001-07-04 2010-05-05 Chromagenics B.V. DNS-Sequenzen mit Anti-Repressor-Aktivität
DK1513937T3 (da) * 2002-06-14 2011-05-16 Chromagenics Bv Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
EP1513936A2 (de) * 2002-06-14 2005-03-16 Chromagenics B.V. Verwendung von repression hemmende sequenzen in verfahren zur genexpression verbesserung
CA2510179C (en) 2002-12-18 2013-04-23 Chromagenics B.V. A method for improving protein production
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können

Also Published As

Publication number Publication date
AU2002314629B2 (en) 2007-08-30
ATE466944T1 (de) 2010-05-15
DK1845162T3 (da) 2010-08-16
EP1806407A2 (de) 2007-07-11
US20070031933A1 (en) 2007-02-08
US20070031935A1 (en) 2007-02-08
SG143066A1 (en) 2008-06-27
CA2450020A1 (en) 2003-01-16
BR0210771A (pt) 2004-07-13
EP1806407A3 (de) 2008-06-04
EP1600510A2 (de) 2005-11-30
DE60236379D1 (de) 2010-06-24
EP1404872B1 (de) 2006-10-18
AU2011202193A1 (en) 2011-06-02
NO338477B1 (no) 2016-08-22
BRPI0210771B8 (pt) 2021-05-25
US20070128717A1 (en) 2007-06-07
ES2344072T3 (es) 2010-08-17
US7749733B2 (en) 2010-07-06
US7951586B2 (en) 2011-05-31
KR20090037485A (ko) 2009-04-15
US7736869B2 (en) 2010-06-15
DK1808488T3 (da) 2010-10-18
US20070026498A1 (en) 2007-02-01
NO20040011L (no) 2004-03-03
US7655441B2 (en) 2010-02-02
ES2344074T3 (es) 2010-08-17
IL193374A (en) 2010-12-30
US20070031934A1 (en) 2007-02-08
EP1842919B1 (de) 2010-05-05
EP1829972A3 (de) 2007-10-24
US7736870B2 (en) 2010-06-15
DE60219221T2 (de) 2008-01-03
DE60236333D1 (de) 2010-06-17
ZA200309599B (en) 2006-05-31
US20070037256A1 (en) 2007-02-15
JP5014444B2 (ja) 2012-08-29
EP1808488B1 (de) 2010-07-14
CA2812799C (en) 2016-01-26
EP1845162B1 (de) 2010-05-05
BRPI0210771B1 (pt) 2015-12-22
ATE467682T1 (de) 2010-05-15
KR20090037960A (ko) 2009-04-16
EP1829972A2 (de) 2007-09-05
EP1829971A1 (de) 2007-09-05
DE60237048D1 (de) 2010-08-26
CA2450020C (en) 2013-08-13
US20030199468A1 (en) 2003-10-23
IL193373A (en) 2010-12-30
DE60236332D1 (de) 2010-06-17
HK1068652A1 (en) 2005-04-29
ES2348174T3 (es) 2010-11-30
US7192741B2 (en) 2007-03-20
PT1600510E (pt) 2007-06-25
JP2004533262A (ja) 2004-11-04
ES2274045T3 (es) 2007-05-16
EP1829971A3 (de) 2008-06-04
US20070026499A1 (en) 2007-02-01
ATE466942T1 (de) 2010-05-15
CA2812799A1 (en) 2003-01-16
EP1600510B1 (de) 2007-03-28
EP1806407B1 (de) 2010-05-05
EP1829971B1 (de) 2010-05-05
AU2007234619B2 (en) 2011-06-02
JP2010131024A (ja) 2010-06-17
KR100942116B1 (ko) 2010-02-12
DK1842919T3 (da) 2010-08-16
DK1829972T3 (da) 2010-09-13
ATE474053T1 (de) 2010-07-15
AU2011202193B2 (en) 2011-09-29
ATE358183T1 (de) 2007-04-15
DE60236334D1 (de) 2010-06-17
IL159674A0 (en) 2004-06-20
JP2010131025A (ja) 2010-06-17
DE60219221D1 (de) 2007-05-10
CN1524128A (zh) 2004-08-25
EP1600510A3 (de) 2006-02-22
EP1845162A1 (de) 2007-10-17
DK1829971T3 (da) 2010-08-16
JP5014443B2 (ja) 2012-08-29
US7662591B2 (en) 2010-02-16
WO2003004704A2 (en) 2003-01-16
ATE466941T1 (de) 2010-05-15
KR100942117B1 (ko) 2010-02-12
CN1266282C (zh) 2006-07-26
ES2344071T3 (es) 2010-08-17
EP1829972B1 (de) 2010-05-12
EP1842919A1 (de) 2007-10-10
ES2344070T3 (es) 2010-08-17
DK1806407T3 (da) 2010-08-16
US7659094B2 (en) 2010-02-09
US20070031936A1 (en) 2007-02-08
ES2285630T3 (es) 2007-11-16
AU2007234619A1 (en) 2007-12-13
ATE343004T1 (de) 2006-11-15
JP4500044B2 (ja) 2010-07-14
DK1404872T3 (da) 2007-02-19
MXPA03011801A (es) 2005-03-07
DE60236331D1 (de) 2010-06-17
WO2003004704A3 (en) 2003-10-16
US7736868B2 (en) 2010-06-15
EP1808488A2 (de) 2007-07-18
ES2344073T3 (es) 2010-08-17
DK1600510T3 (da) 2007-06-25
DE60215502T2 (de) 2007-08-30
EP1404872A2 (de) 2004-04-07
DE60215502D1 (de) 2006-11-30
EP1808488A3 (de) 2007-11-14
IL159674A (en) 2009-02-11
CY1107678T1 (el) 2013-04-18
NZ530218A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
ATE466942T1 (de) Dns-sequenzen mit anti-repressor aktivität
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
DE60027135D1 (de) Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
ATE416610T1 (de) Wasserfilter
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
ATE340860T1 (de) Methode zur verbesserung der agronomischen und des ernährungswertes von pflanzen
DE60223810D1 (de) Organische nitrat-derivate zur behandlung von atherosklerose und vaskulären erkrankungen
ATE311407T1 (de) Varianten der allergenen proteine der gruppe 2 von dermatophagoides
DE60131682D1 (de) Biologische bekämpfung von pflanzenkrankheiten
ATE374834T1 (de) Methoden zur identifizierung evolutionär signifikanter änderungen in polynukleotid- und polypeptidsequenzen in domestizierten pflanzen und tieren
ATE310392T1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
DE50203158D1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
ITGE20040063A1 (it) Metodo per incrementare l'efficacia biologica dei campi elettromagnetici usati per il trattamento di esseri umani animali o piante.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1842919

Country of ref document: EP